Antinuclear Antibodies in Pregnancy

Introduction to ANA in Pregnancy

• The American Association for the Study of Liver Diseases (AASLD) recommends evaluating antinuclear antibodies (ANA) in pregnant women with abnormal liver tests 1, 2

Diagnostic Evaluation

• The AASLD guidelines suggest testing for specific autoantibodies, including anti-smooth muscle, anti-mitochondrial, and primary biliary cirrhosis-specific antibodies, in pregnant women with abnormal liver tests 1, 2
• Quantitative IgG levels should be assessed to evaluate for autoimmune hepatitis 1, 2
• Other causes of liver disease, such as viral hepatitis, celiac disease, and Wilson's disease, should be excluded 1, 2

Monitoring and Management

• Women with anti-Ro/SSA and/or anti-La/SSB antibodies should undergo serial fetal echocardiography starting at 16-18 weeks of gestation 4, 5
• The frequency of echocardiography should be weekly if there is a history of congenital heart block or neonatal lupus 4, 5
• The risk of complete heart block is 2% in the first pregnancy and 13-18% in subsequent pregnancies after a affected newborn 4, 5

Interpretation of Test Results

• Persistent ANA positivity with high titers or positive specificities requires rheumatologic consultation to rule out systemic lupus erythematosus or other connective tissue diseases 5
• Transient or low-titer ANA without specificities can be reassuring, with no specific treatment necessary 5
• Follow-up should include clinical evaluation and potential re-testing post-partum or after an acute event 1, 7, 3